abstract |
Antibody polypeptides that specifically bind to a novel epitope of human CD40 are provided. This antibody polypeptide does not exhibit CD40 agonist activity. This antibody polypeptide is useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptide can be a domain antibody (dAb) comprising a single VL or VH domain. The half-life of the antibody polypeptide can be increased by modifying the antibody polypeptide to be a bispecific reagent that can also bind to human serum albumin (HSA). |